Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approving the Investigational New Drug (IND) application for its novel dual-payload ADC drug, SKB565, for the treatment of advanced solid tumors. This marks the Company's first dual-payload ADC to enter the clinical stage.

Leveraging technological expertise and platform advantages in the ADC field, Kelun-Biotech has established a diversified pipeline of innovative molecules featuring high-value targets, differentiated designs, and global potential. Building on this foundation, the Company continues to advance its "ADC + IO" strategy—on one hand by actively exploring high-quality combination regimens, including multiple ongoing clinical studies evaluating ADCs in combination with PD-(L)1 monoclonal antibodies, as well as the PD-1/VEGF bispecific antibody SKB118 in combination with its proprietary ADC portfolio; on the other hand, the Company is advancing integrated drug design strategies by incorporating synergistic functional components into a single ADC molecule.

Dr. Michael Ge, CEO of Kelun-Biotech, said, " SKB565 is one of the core representative drugs of our integrated 'ADC + IO' strategy, leveraging the synergistic mechanism of its dual payloads to enhance efficacy and overcome drug resistance. Dual-payload ADCs are emerging as one of the key next-generation innovations in the ADC field. The advancement of SKB565 into clinical stage not only marks an important milestone in the achievements transformation of our technology platform, but also substantiates the continued deepening of our innovation capabilities in ADCs. We will actively advance the clinical development of novel drug conjugates such as SKB565, striving to deliver greater benefits to patients with cancer as soon as possible."